Australian Clinical Labs (ASX:ACL): Final Dividend Signals Another Shareholder Payout

Aditi Sarkar

01 September 2026 07:53 PM AEST

Australian Clinical Labs (ASX:ACL): Final Dividend Signals Another Shareholder Payout

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Australian Clinical Labs Ltd has announced a 100% franked final Dividend of 9.2 cents per share.
The stock is scheduled to go ex-dividend on 2 September 2026, with payment due on 23 September 2026.
The Dividend Yield is 3.30% based on a share price of AUD 2.80.
The dividend forms part of the company's latest Shareholder distribution update.

Australian Clinical Labs Ltd (ASX:ACL) is approaching its next shareholder distribution with a 9.2-cent fully franked final dividend due in September. The payment places the company’s latest Capital return in focus as investors track the ex-dividend date, payment timetable and dividend yield.

Dividend Details Take Centre Stage

The company has declared a final dividend of 9.2 cents per share and is 100% franked. The shares are scheduled to trade ex-dividend on 2 September 2026, while the payment date is set for 23 September 2026. These dates are central for shareholders assessing eligibility for the upcoming distribution.

Income Profile in Focus

The current market picture shows that the dividend yield is 3.30%, with the share price at AUD 2.80. The yield provides a current reference point for assessing the cash distribution relative to the stated share price, while the franking level provides additional detail on the tax character of the payment.

Latest Company Update

Australian Clinical Labs has continued expanding its pathology offering, with recent company updates highlighting CNSDose availability through its network and further clinical developments including long-term data on EndoPredict. These activities sit alongside the company’s latest FY26 shareholder distribution.

What the Upcoming Payment Means for Shareholders

The upcoming dividend places the company's shareholder distribution policy in focus. Investors tracking the payment should note the ex-dividend date of 2 September 2026 and the scheduled payment date of 23 September 2026, alongside the 9.2 cents per-share distribution and 100% franking level.

Dividend Dates to Watch

For the current distribution, the key dates are the 2 September 2026 ex-dividend date and 23 September 2026 payment date. The share price is AUD 2.80, while the indicated dividend yield is 3.30%. Together, these details provide the key snapshot for shareholders monitoring the upcoming payment.

FAQs

Q:What dividend has Australian Clinical Labs Ltd announced?

A:Australian Clinical Labs Ltd has announced a final dividend of 9.2 cents per share, 100% franked.

Q:When is the ex-dividend date?

A:The stock is scheduled to go ex-dividend on 2 September 2026.

Q:When will the dividend be paid?

A:The scheduled payment date is 23 September 2026.

Q:What is the indicated dividend yield?

A:The dividend yield is 3.30%, based on a share price of AUD 2.80.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.